Depomed (NASDAQ: DEPO) reported Q3 EPS of $0.14, $0.03 better than the analyst estimate of $0.11. Revenue for the quarter came in at $95 million versus the consensus estimate of $99.57 million.

GUIDANCE:

Depomed sees FY2017 revenue of $375-380 million, versus the consensus of $393.6 million.

For earnings history and earnings-related data on Depomed (DEPO) click here.